Clinical predictors of SARS-CoV-2 vaccine immunogenicity in kidney transplant recipients at a rural center

Table 3 Linear regression analysis of factors associated with log-transformed antibody titer among responders

Variable	Coefficient	Standard error	95%CI	P value
Age (per year increase)	-22.6	47.5	-118.2 to 73.1	0.64
Gender (male vs female)	-1153.4	1138.2	-3444.4 to 1137.6	0.32
Race	-148.9	1488.7	-3145.5 to 2847.6	0.92
Days from transplant to first vaccine	-0.2	0.5	-1.2 to 0.7	0.62
Days from 2nd vaccine to sample testing	2.1	7.8	-13.6 to 17.9	0.79
Tacrolimus level	-42.5	303.5	-653.5 to 568.5	0.89
MPA dose (mg/day)	1.9	2.9	-3.9 to 7.8	0.51
Diabetes mellitus	-1957.9	1701	-5381.8 to 1466.0	0.26
Hypertension	-98.3	1568.2	-3254.8 to 3058.2	0.95
Vaccine type	-232.3	1011.9	-2269.2 to 1804.6	0.82
SPK or kidney alone	-1152.1	2005	-5188.1 to 2883.8	0.57
History of rituximab use	950.3	1837.7	-2748.7 to 4649.4	0.61
Type of donor (living vs deceased)	-547.1	1798.1	-4166.5 to 3072.2	0.76
Previous transplant (yes vs no)	-2029.9	1537	-5123.7 to 1063.8	0.19
Primary ESRD etiology	-202.5	332.3	-871.3 to 466.3	0.55
Constant	23867.3	5273.3	13252.8 to 34481.8	0

Reference categories for regression models were female sex, other race, absence of induction therapy, absence of calcineurin inhibitor, absence of antimetabolite therapy, absence of steroid therapy, receipt of non-mRNA vaccine, deceased donor transplantation, and absence of the listed comorbidities, unless otherwise specified. MPA: Mycophenolic acid; SPK: Simultaneous pancreas kidney; ESRD: End stage renal disease; 95%CI: 95% confidence interval.